In his third lecture, Gadek outlines Lifitegrast clinical trials, from Phase 1 to Phase 3, and presents evidence of Lifitegrast’s safety profile in normal individuals as well as the efficacy of the drug in treating dry eye syndrome. Lifitegrast’s story shows the different layers of drug development and the steps that companies go through to take a drug from the laboratory to the patient’s bedside and ultimately to the market.
View the full talk with additional resources on our website
The Development of Lifitegrast to Treat Dry Eye Syndrome
Tom Gadek goes through all of the steps in financing, developing, testing and producing Lifitegrast, a drug for treating dry eye syndrome. (Talk recorded in June 2016)
- Part 1: The SARcode Story: How to build a biotech companyAudience:
- Researcher
- Educators of H. School / Intro Undergrad
- Educators of Adv. Undergrad / Grad
Duration: 49:51 - Part 2: Discovery and development of Lifitegrast to treat dry eye syndrome: PharmacologyAudience:
- Educators of H. School / Intro Undergrad
- Educators of Adv. Undergrad / Grad
Duration: 30:30 - Part 3: Discovery and development of Lifitegrast: Clinical StudyAudience:
- Educators of H. School / Intro Undergrad
- Educators of Adv. Undergrad / Grad
Duration: 38:49